New treatment to help hemophilia patients manage immune responses
Immunocytokine therapy for immune modulation in hemophilia
This study is looking at a new treatment that uses a special protein to help the immune system work better for people with hemophilia who have trouble with their clotting factor therapy, aiming to make their treatment easier and more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11041250 on NIH RePORTER |
What this research studies
This research investigates a novel immunocytokine therapy aimed at improving immune tolerance in patients with hemophilia who develop inhibitors against clotting factor replacement therapy. The approach focuses on utilizing a specific cytokine, IL-2, to enhance the function of regulatory T cells, which are crucial for preventing the immune system from attacking the replacement therapy. By minimizing the adverse effects associated with current treatments, this therapy seeks to reduce the frequency of infusions and improve overall patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with hemophilia who have developed inhibitors against clotting factor replacement therapy.
Not a fit: Patients who do not have hemophilia or those who have not developed inhibitors against clotting factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and less burdensome treatment option for hemophilia patients, reducing complications and improving their quality of life.
How similar studies have performed: While the approach of using immunocytokines is innovative, similar strategies targeting immune modulation in other conditions have shown promise, suggesting potential for success in this area as well.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Biswas, Moanaro — Indiana University Indianapolis
- Study coordinator: Biswas, Moanaro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.